PHASE I TRIAL OF AMINOPTERIN IN PATIENTS WITH REFRACTORY MALIGNANCIES

$321,374M01FY2002RRNIH

University Of Texas Sw Med Ctr/Dallas, Dallas TX

Investigators

Linked publications & trials

Paper 35728925 Paper 34669075 Paper 33478957 Paper 32779294 Paper 32111975 Paper 31691959 Paper 31427096 Paper 31221698 Paper 31005534 Paper 30737489 Paper 30631138 Paper 29874658 Paper 29872859 Paper 28647272 Paper 28283553 Paper 28199816 Paper 27455401 Paper 27423510 Paper 27074126 Paper 26679435 Paper 26080344 Paper 25424574 Paper 25213055 Paper 24886531 Paper 24665001 Paper 24552753 Paper 24378638 Paper 24370654 Paper 24344119 Paper 24331012 Paper 24325736 Paper 24113734 Paper 24067395 Paper 24008162 Paper 23867957 Paper 23800548 Paper 23783098 Paper 23762536 Paper 23687099 Paper 23447519 Paper 23418044 Paper 23404728 Paper 23219305 Paper 23187859 Paper 23139080 Paper 23080496 Paper 22990274 Paper 22984143 Paper 22939555 Paper 22926660 Paper 22811446 Paper 22748517 Paper 22739230 Paper 22688849 Paper 22644414 Paper 22641777 Paper 22571902 Paper 22499082 Paper 22359532 Paper 22331415 Paper 22297671 Paper 22247230 Paper 22170723 Paper 22114147 Paper 22100029 Paper 22067724 Paper 22065155 Paper 22045670 Paper 22002999 Paper 21976719 Paper 21946897 Paper 21931376 Paper 21930284 Paper 21917261 Paper 21829595 Paper 21818156 Paper 21817103 Paper 21782771 Paper 21760886 Paper 21734082 Paper 21699796 Paper 21690484 Paper 21681226 Paper 21562061 Paper 21555334 Paper 21520194 Paper 21508291 Paper 21480316 Paper 21440548 Paper 21376050 Paper 21374690 Paper 21335007 Paper 21257113 Paper 21254377 Paper 21232706 Paper 21211932 Paper 21139575 Paper 21139111 Paper 21136163 Paper 21135351

Abstract

The purpose of this study is (1) to establish the qualitative and quantitative toxicity of aminopterin in children and adults, (2) to determine the acute dose-limiting toxicities and time(s) to recovery, (3) to determine if there is cumulative toxicity, (4) to establish a maximum-tolerated dose of aminopterin that results in tolerable toxicity which is predictable and reversible and can be used in phase II trials, (5) to determine the minimal amount of leucovorin rescue that is needed to protect from excessive tosicity, and (6) to determine precautions and supportive therapy that should be used.

View original record on NIH RePORTER →